On May 14, 2025, Cantor Fitzgerald analyst Timur Ivannikov maintained an "Overweight" rating for Pharvaris (PHVS, Financial). The analyst continued to show confidence in the stock, despite a revision in the price target.
The new target price set by Cantor Fitzgerald for Pharvaris (PHVS, Financial) is $25.00 USD, a 10.71% decrease from the previous target of $28.00 USD. This adjustment reflects the analyst's changing expectations but does not alter the overall positive outlook, as the rating remains "Overweight".
Investors and stakeholders are closely monitoring the updates on Pharvaris (PHVS, Financial) to understand market perspectives and analyst insights. The revised price target aims to align with current market dynamics while maintaining a positive stance on the stock's potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Pharvaris NV (PHVS, Financial) is $33.12 with a high estimate of $55.02 and a low estimate of $14.01. The average target implies an upside of 113.01% from the current price of $15.55. More detailed estimate data can be found on the Pharvaris NV (PHVS) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Pharvaris NV's (PHVS, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
